# Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma

> **NCT06251180** · PHASE1 · RECRUITING · sponsor: **Guangzhou Lupeng Pharmaceutical Company LTD.** · enrollment: 112 (estimated)

## Conditions studied

- B-cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Rocbrutinib
- **BIOLOGICAL:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** doxorubicin
- **DRUG:** Vincristin
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT06251180
- **Lead sponsor:** Guangzhou Lupeng Pharmaceutical Company LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-10
- **Primary completion:** 2025-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2025-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06251180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06251180, "Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06251180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*